Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of Balcinrenone in Renal Impairment
NCT04469907Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of balcinrenone in chronic kidney disease (CKD) and heart failure (HF), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to infinity and 6 more. Started Jun 2020; status: completed.
02
Drugs
balcinrenone
03
Conditions
chronic kidney disease (CKD)heart failure (HF)
Beyond the preview
Go deeper on NCT04469907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469907.